ArticleMolecular and cellular probes2012
Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.
Article in Molecular and cellular probes, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 51 citations in OpenAlex.
- Trial
- Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men.Vaccine · 2019Trial
- Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.Human vaccines & immunotherapeutics · 2013Trial
- Development of HPV 35 serology assays for assessment of immune responses to HPV 35 after infection and vaccination.Human vaccines & immunotherapeutics · 2026Article
- Memory Cell and Antibody Responses Following a Single Versus Two Doses of Escherichia coli-Produced Vaccine Against Human Papillomavirus Types 16 and 18: A Real-World Study in Chinese Girls.International journal of cancer · 2026Article
- Developmental exposure to a PFAS mixture impairs the anamnestic response to influenza A virus infection in mice.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Susceptibility of naturally human papillomavirus type 16 major capsid protein L1 variants to vaccines and predictions of future evolutionary trends.Tumour virus research · 2026Article
- Article
- Decreased Fc fucosylation aligns with enhanced RSV-specific antibody functionality in adults compared to young children.Communications medicine · 2025Article
- Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters.Communications biology · 2025Article
- Developmental exposure to a PFAS mixture impairs the anamnestic response to influenza A virus infection in mice.bioRxiv : the preprint server for biology · 2025Article
- Detection of mpox and other orthopoxviruses using a lateral flow device as a point-of-care diagnostic.Microbiology spectrum · 2025Article
- Helminth driven gut inflammation and microbial translocation associate with altered vaccine responses in rural Uganda.NPJ vaccines · 2025Article
- Timing influences the impact of aryl hydrocarbon receptor activation on the humoral immune response to respiratory viral infection.Toxicology and applied pharmacology · 2024Article
- Development of conjugated secondary antibodies for wildlife disease surveillance.Frontiers in immunology · 2023Article
- Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.iScience · 2022Article
- The Aryl Hydrocarbon Receptor Modulates T Follicular Helper Cell Responses to Influenza Virus Infection in Mice.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Article
- Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine.NPJ vaccines · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Antibody responses against infectious agents are an important component in the prevention of disease. The avidity of antibodies for their antigens relates to their functional efficiency, and is a fundamental aspect in the investigation of humoral responses. Modified ELISAs are used to estimate avidity through the use of chaotropic agents and the measurement of the degree to which they disrupt the interaction between antibody and antigen. The theory behind the assay is the higher the avidity of an interaction the less susceptible it is to the effects of the chaotropic agent. The goal of this study was to generate a modified ELISA where a complex, multimeric coating-antigen, human papillomavirus (HPV) virus-like particles (VLP), was used to measure the avidity of anti-HPV antibodies generated following vaccination with HPV VLPs. A series of chaotropic agents were evaluated in the assay for their effectiveness in measuring avidity. Guanidine hydrochloride (GuHCl) was selected as a chaotropic reagent with the ability to disrupt antibody and antigen interactions, while not affecting the integrity of the plate-bound VLP. Two methods of determining the avidity index were assessed and shown to be comparable. This assay was then successfully applied to measure the avidity of anti-HPV VLP serum antibodies in samples from an HPV L1 VLP vaccine clinical trial. Overall, the assay was highly reproducible and captured a wide range of antibody avidities. Therefore, a GuHCl-modified ELISA is an acceptable method that can be used to determine HPV-specific antibody avidity indices within a clinical trial setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.